0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Pathological Case of the Month FREE

[+] Author Affiliations

Section Editor: Enid Gilbert-barness, MD

More Author Information
Arch Pediatr Adolesc Med. 2000;154(9):962. doi:.
Text Size: A A A
Published online

DIAGNOSIS AND DISCUSSION: NEUROFIBROMATOSIS 2 WITH BILATERAL VESTIBULAR SCHWANNOMAS AND SPINAL CORD EPENDYMOMA

Figure 1. A large mass involving the lower thoracic and upper lumbar spinal cord segments and multiple masses involving nerve roots of the cauda equina.

Figure 2. Cranial magnetic resonance image showing bilateral masses. involving the seventh and eighth cranial nerves.

Figure 3. Spinal cord ependymoma consisting of a cellular neoplasm composed of small blue cells alternating with acellular fibrillary areas (perivascular pseudorosettes) surrounding blood vessels (hematoxylin-eosin, original magnification ×100).

Figure 4. High-power view of ependymoma with perivascular pseudorosettes (hematoxylin-eosin, original magnification ×400).

The neurofibromatoses (NF) comprise a group of disorders characterized by an autosomal dominant genetic predisposition to the development of various neural crest cell neoplasms. Although any organ system can be involved, the tumors typically affect the skin and nervous system. Currently, 8 subtypes are recognized.1 The best-described variants, NF 1 and 2, were once designated peripheral and central NF, respectively. However, use of those terms is inappropriate because either condition can involve the central or peripheral nervous systems.2 Molecular tests have confirmed that they are genetically distinct conditions.

Neurofibromatosis 1 occurs in approximately 1:3000 to 1:4000 individuals.1,3,4 It localizes to a genetic defect on chromosome 17q.3,4 Café au lait spots, freckling of the axillary and inguinal regions, peripheral neurofibromas, and Lisch nodules are the cardinal features.3,5,6 Plexiform neurofibromas and central nervous system tumors such as optic nerve gliomas are common sequelae.1 Although NF 1 is autosomal dominant, 50% of cases represent new mutations.3,5,6

With an estimated incidence of 1:40,000,1,3,4 NF 2 is seen less frequently. The NF 2 gene has been localized to chromosome 22q12.7 Studies suggest that the NF 2 gene functions as a tumor suppressor.8 Most individuals with NF 2 develop the hallmark feature, bilateral vestibular schwannomas, by the second or third decade.24 They typically have progressive and unilateral hearing loss; many initially notice this when using the telephone.2,4 Tinnitus and vertigo are other common symptoms.2 Facial weakness, sensory changes, ataxia, headaches, and diplopia may also be present.4 Approximately 30% of patients with NF 2 have nonvestibular schwannomas, and 50% develop intracranial meningiomas.3 Spinal cord tumors, usually ependymomas, and meningiomas are common,3 affecting up to 89% of patients in one series.9 More than half of patients with NF 2 have peripheral nerve tumors, usually schwannomas, appearing as plaques, nodules, or cutaneous neurofibromas and resembling those seen in NF 1.5 Most patients with NF 2 have ocular lesions. Cataracts, retinal hamartomas, epiretinal membranes, and optic disc gliomas may also develop.5 Café au lait spots are not nearly as frequent as in NF 1 cases.5 The diagnosis of NF 2 should be considered in any child with a posterior cataract, peripheral nerve neoplasms,3 or multiple central nervous system tumors, particularly in the absence of café au lait spots or Lisch nodules.3,10

Diagnostic criteria11 include (1) bilateral vestibular schwannomas, observed by MRI; and (2) a first-degree relative with NF 2 and either a unilateral vestibular schwannoma or any 2 of the following: meningioma, glioma, schwannoma, juvenile subcapsular lenticular opacities/juvenile cortical cataracts.6 Family members are at risk. The condition is autosomal dominant, with a 50% risk of penetrance. The NF 2 gene can be identified by direct molecular genetic testing.5,6,10 First-degree relatives require a thorough ophthalmologic and neurologic examination. Newly diagnosed patients and at-risk family members must be counseled about balance disturbances and should exercise caution when swimming, diving,2 or climbing at high altitudes.6

Adequate treatment of NF 2 requires a strong collaborative effort between multiple specialists. Newly diagnosed individuals should undergo full MRI (with and without gadolinium) of the head and spinal cord. Thorough neurologic, skin, and ophthalmologic examinations are requisite.4 Clinical workup should also include brainstem auditory-evoked responses and audiometry testing for hearing dysfunction.4,6 Treatment modalities can include observation, surgery, and radiation. With resection of vestibular tumors, there is a risk of permanent sequelae. Optimally, a vestibular schwannoma can be excised with minimum morbidity and mortality,2 particularly small tumors that are confined to the internal auditory canal. Spinal cord tumors should be closely followed by MRI. Spinal cord meningiomas and nerve sheath tumors tend to be slow growing and multiple2,3; they may reach a large size before becoming clinically evident.3 Pollack and Mulvihill3 recommend resection of tumors that compress the spinal cord. Generally, most glial hamartomas and low-grade gliomas, both common in NF 2, are not aggressive.2

Accepted for publication April 30, 2000.

Reprints: Sonya Arnold, MD, Box 1289, Tampa General Hospital, Tampa, FL 33601.

Riccardi  VM Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 2nd ed. Baltimore, Md The Johns Hopkins University Press1992;
Martuza  RLEldridge  R Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988;318684- 688
Link to Article
Pollack  IFMulvihill  JJ Neurofibromatosis 1 and 2. Brain Pathol. 1997;7823- 836
Link to Article
Zoghbi  HYBallabio  A Neurofibromatosis 2. Scriver  CRBeaudet  ALSly  WSValle  Deds.The Metabolic and Molecular Basis of Inherited Disease 7th ed. New York, NY McGraw-Hill, Inc1995;4593- 4597
Huson  SMRosser  EM The phakomatoses. Rimoin  DLConnor  JMPyeritz  REeds.Emery and Rimoin's Principles and Practice of Medical Genetics 3rd ed. New York, NY Churchhill Livingstone1996;2269- 2281
Gutmann  DHAylsworth  ACarey  JC  et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;27851- 57
Link to Article
Rouleau  GAMerel  PLutchman  M  et al.  Alteration in a new gene encoding a putative membrane organizing protein causes a neurofibromatosis type 2. Nature. 1993;363515- 521
Link to Article
Seizinger  BRRouleau  GOzelius  LJ  et al.  Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science. 1987;236317- 319
Link to Article
Mautner  VFTatagiba  MLindenau  M  et al.  Spinal tumors in patients with neurofibromatosis 2. AJR Am J Roentgenol. 1995;165951- 955
Link to Article
Mautner  VFTatagiba  MGuthoff  R  et al.  Neurofibromatosis in the pediatric age group. Neurosurgery. 1993;3392- 96
Link to Article
National Institutes of Health Conference, Neurofibromatosis: Conference Statement. Arch Neurol. 1988;45575- 578
Link to Article

Tables

References

Riccardi  VM Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 2nd ed. Baltimore, Md The Johns Hopkins University Press1992;
Martuza  RLEldridge  R Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988;318684- 688
Link to Article
Pollack  IFMulvihill  JJ Neurofibromatosis 1 and 2. Brain Pathol. 1997;7823- 836
Link to Article
Zoghbi  HYBallabio  A Neurofibromatosis 2. Scriver  CRBeaudet  ALSly  WSValle  Deds.The Metabolic and Molecular Basis of Inherited Disease 7th ed. New York, NY McGraw-Hill, Inc1995;4593- 4597
Huson  SMRosser  EM The phakomatoses. Rimoin  DLConnor  JMPyeritz  REeds.Emery and Rimoin's Principles and Practice of Medical Genetics 3rd ed. New York, NY Churchhill Livingstone1996;2269- 2281
Gutmann  DHAylsworth  ACarey  JC  et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;27851- 57
Link to Article
Rouleau  GAMerel  PLutchman  M  et al.  Alteration in a new gene encoding a putative membrane organizing protein causes a neurofibromatosis type 2. Nature. 1993;363515- 521
Link to Article
Seizinger  BRRouleau  GOzelius  LJ  et al.  Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science. 1987;236317- 319
Link to Article
Mautner  VFTatagiba  MLindenau  M  et al.  Spinal tumors in patients with neurofibromatosis 2. AJR Am J Roentgenol. 1995;165951- 955
Link to Article
Mautner  VFTatagiba  MGuthoff  R  et al.  Neurofibromatosis in the pediatric age group. Neurosurgery. 1993;3392- 96
Link to Article
National Institutes of Health Conference, Neurofibromatosis: Conference Statement. Arch Neurol. 1988;45575- 578
Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles